Development of a single item patient reported measure of treatment side effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement

By afschroeder • June 28, 2026

Berthelsen DB, Horgan B, Simon L, Ioannidis JPA, Goel N, Tugwell P, Balay-Dustrude E, Bartlett SJ, Bingham CO, Boers M, Bouillot C, Böhm P, Choy E, Cowern M, Dagsvik K, Djurtoft C, Furst DE, Haugegaard T, Hazlewood GS, Hoens AM, Jørgensen TS, Kelly SE, Kruzikas D, Musaus J, Richards P, Shea BJ, Strand V, Thomas M, Torralba K, Voshaar M, Weinbrecht-Mischkewitz M, Woodworth TG, Wright G, Flurey C, Christensen R; OMERACT Safety Working Group. Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement. Semin Arthritis Rheum. 2026 Jun 19;79:153026. doi: 10.1016/j.semarthrit.2026.153026. Epub ahead of print. PMID: 42364594.

Tags: Adverse events, Core outcome set, Harms, Large language model, OMERACT, Publications, Rheumatology, rheumatology, safety

Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis

Ravani LV, Bagheri Z, Kalinsky K, Burstein HJ, Bardia A, Mouabbi JA, O'Regan R, Wander SA. Progression-Free Survival in Metastatic Breast Cancer by Local Investigators[...]

Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed

Orchard P, Blackwell TW, Kachuri L, Castaldi PJ, Cho MH, Christenson SA, Durda P, Gabriel S, Hersh CP, Huntsman S, Hwang S, Joehanes R, Johnson[...]

Chronological versus physiological age for 10-year survival estimation: a real-world healthsystem-wide cohort analysis

Justice AC, Tate JP, McGinnis KA, Torgersen JL, Braithwaite RS, Marconi VC, Goetz MB, Rodriguez-Barradas MC, Brown ST, Park L, Oursler KAK, Womack JA, Becker[...]